Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 17149 pages

Showing 9451 - 9500


colorectal cancer
immunotherapy

Alan P. Venook, MD, on Selecting Treatment for Advanced Colorectal Cancer

Alan P. Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses which biomarkers to order and when, the role of checkpoint inhibitors, and chemotherapy choices.

pancreatic cancer

Gut Bacteria May Determine Speed of Tumor Growth in Pancreatic Cancer

The population of bacteria in the pancreas increases more than a thousandfold in patients with pancreatic cancer and becomes dominated by species that prevent the immune system from attacking tumor cells. These are the findings of an early study conducted on pancreatic ductal adenocarcinoma,...

lymphoma

FDA Updates Public Information About Known Risk of Lymphoma From Breast Implants

On March 21, the U.S. Food and Drug Administration (FDA) issued updated information about its understanding of breast implant–associated anaplastic large cell lymphoma (ALCL). The agency is providing an updated number of medical device reports (ie, adverse event reports) and medical...

leukemia

FDA Expands Nilotinib Indication to Pediatric Patients With CML

Today, the U.S. Food and Drug Administration (FDA) expanded the indication for nilotinib (Tasigna) to include treatment of first- and second-line pediatric patients 1 year of age or older with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase. In the United...

leukemia

Ellin Berman, MD, on CML: Disease Management During Pregnancy

Ellin Berman, MD, of Memorial Sloan Kettering Cancer Center, discusses the effects of TKI therapy on fetal development, its impact on pregnancy outcomes, and how to develop an effective treatment plan.

prostate cancer

EAU 2018: Prostate MRI Reveals More Clinically Significant Cancers, Reduces Overdiagnosis Compared to Standard Biopsy

A large international study has shown that magnetic resonance imaging (MRI) can reduce the number of invasive prostate biopsies by up to 28%. The PRECISION trial showed that using MRI to target prostate biopsies leads to more harmful and fewer harmless prostate cancers being diagnosed. The results...

solid tumors

EAU 2018: Study Finds a Quarter of Penile Cancer Patients Do Not Receive Recommended Treatment

A major international survey has found that around a quarter of patients with penile cancer are not receiving the recommended treatment, and that these patients had half the survival rate of those who were treated according to guidelines. The study, presented at the European Association of Urology...

kidney cancer
prostate cancer
bladder cancer

EAU 2018: Survey Shows Greater Suicide Rate in Patients With Urologic Cancers

A major UK survey has shown that patients with urologic cancer—such as prostate, bladder, or kidney cancer—are five times more likely to commit suicide than people without cancer. The analysis also shows that patients with cancer generally are around three times more likely to commit...

prostate cancer

FDA Grants Priority Review to sNDA for Enzalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

On March 19, a supplemental New Drug Application (sNDA) for enzalutamide (Xtandi) was accepted for filing and granted Priority Review designation by the U.S. Food and Drug Administration (FDA). If approved, the sNDA would expand the indication of enzalutamide to include men with nonmetastatic...

lymphoma
immunotherapy

FDA Expands Approval of Brentuximab Vedotin for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination With Chemotherapy

On March 20, the U.S. Food and Drug Administration (FDA) approved brentuximab vedotin (Adcetris) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy. “Today’s approval represents an improvement in the initial...

Conquer Cancer Foundation Recognizes 70 Young Oncology Researchers’ Findings With Merit Awards

ASCO’s Conquer Cancer Foundation is pleased to announce the recipients of its Merit Awards in gastrointestinal cancers, clinical immuno-oncology, genitourinary cancers, and cancer survivorship. The following 70 researchers— oncology fellows and trainees honored for the quality and scientific merit...

issues in oncology

New NCCN Guidelines Aim to Encourage More People Living With HIV and Cancer to Receive Appropriate Cancer Treatment

The National Comprehensive Cancer Network® (NCCN) has released new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) intended to help make sure people living with human immunodeficiency virus (HIV) who are diagnosed with cancer receive safe, necessary treatment.  According to a...

Frederick National Laboratory and Georgetown University Launch Research Collaboration

A new collaboration established between Georgetown University and the Frederick National Laboratory for Cancer Research aims to expand both institutions’ research and training missions in the biomedical sciences. Representatives from Georgetown University and the Frederick National Laboratory...

hematologic malignancies
leukemia

Martin S. Tallman, MD, Joins Samuel Waxman Cancer Research Foundation’s Scientific Advisory Board

The Samuel Waxman Cancer Research Foundation (SWCRF) announced that Martin S. Tallman, MD, Chief of Leukemia Service at Memorial Sloan Kettering Cancer Center (MSK), has joined its Scientific Advisory Board. Dr. Tallman, who will continue in his role at MSK, will join his fellow Scientific...

issues in oncology
survivorship

Impact of Lifestyle Choices on Outcomes in Survivors of Gastrointestinal Cancers

Physical inactivity among adult survivors of gastrointestinal cancers was tied to poor health-related quality of life, according to researchers at the American Psychosocial Oncology Society (APOS) Annual Meeting.1 Also, physical inactivity (Chi-square = 5.605, P = .018) and alcohol use (Chi-square ...

breast cancer

TAILORx Trial Results Aid in Assessing the Effect of Chemotherapy in Women With Early-Stage Breast Cancer

On March 15, Genomic Health, Inc, was informed by the ECOG-ACRIN Cancer Research Group that the TAILORx trial, has achieved sufficient information to render a conclusion regarding the efficacy of chemotherapy in patients with early-stage breast cancer who have Oncotype DX recurrence score...

prostate cancer

Study Finds Shared Decision-Making Still Lacking in Prostate Cancer Screening

A new study found many men receiving prostate-specific antigen (PSA) testing do so without a comprehensive shared decision-making process, contrary to current guidelines. The American Cancer Society study, published by Fedewa et al in Annals of Family Medicine, found that in both 2010 and 2015,...

gastrointestinal cancer
colorectal cancer

Studies Explore Colon Tumor Sidedness, Lung Radiation Dose in Esophageal Cancer, Pembrolizumab in Liver Cancer, and More

Along with full coverage of key presentations from the 2018 Gastrointestinal Cancers Symposium, The ASCO Post brings our readers this additional news roundup.  Side Matters in Colon Cancer One of the studies included in the global IDEA trial, which compared 3 vs 6 months of adjuvant chemotherapy in ...

solid tumors

Testicular Cancer Survivors and Adequate Screening for Long-Term Heart Disease

Testicular cancer is the most common cancer in young men. The majority of patients are cured of their disease, but a newly published study shows many remain at risk for later complications from chemotherapy or other treatments. The study, published by Zaid et al in JNCCN –Journal of the...

breast cancer

ASTRO Issues New Clinical Guideline for Whole-Breast Radiation Therapy

The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the use of whole-breast radiation therapy for breast cancer that expands the population of patients recommended to receive hypofractionated treatment. The guideline was published by Smith et al in...

issues in oncology

Cancer Drug Development Award Given to Jean-Charles Soria, MD, PhD

  The Targeted Anticancer Therapies 2018 Honorary Award for cancer drug development has been granted to Jean-Charles Soria, MD, PhD, for his pioneering role in cancer drug development across molecular targeted agents, precision medicine, and immunotherapy. The award was presented during the 2018...

issues in oncology
legislation

Why Right-to-Try Laws Are Dangerous

Why wouldn’t you support a patient with a terminal illness the “right to try” any therapy that may save his or her life? The answer to this question—one engulfed in a political debate in Congress—seems simple. It is not. [Editor’s Note: [Editor’s Note: On May 30, 2018, the President signed into...

solid tumors

Poorer Socioeconomic Status May Predict Lower Survival in Patients With Anal Cancer

Patients with lower income have a significantly reduced chance of surviving anal cancer, according to a new study led by investigators at NYU Langone Health’s Perlmutter Cancer Center published by Lin et al in the journal Cancer. The study shows that both overall and...

bladder cancer

FDA Grants Breakthrough Therapy Designation to Erdafitinib for the Treatment of Metastatic Urothelial Cancer

On March 15, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to erdafitinib for the treatment of urothelial cancer. Urothelial cancer, most frequently in the bladder, is the sixth most common type of cancer in the United States. A Breakthrough Therapy ...

breast cancer

AACR 2018: Acquired HER2 Mutations Confer Resistance to Hormone Therapy in ER-Positive Metastatic Breast Cancer

Mutations in HER2 were found to confer resistance to hormone therapy in some estrogen receptor (ER)-positive metastatic breast cancer cases, and resistance could be reversed by dual treatment with the hormone therapy fulvestrant (Faslodex) and the HER2 kinase inhibitor neratinib (Nerlynx),...

solid tumors
hematologic malignancies

AACR 2018: Prior Chemotherapies May Impair Pediatric Patients’ Ability to Develop Effective CAR T Cells

Pediatric patients with solid tumors may have poor quality T cells compared to patients with leukemia, and certain chemotherapies were detrimental to the T cells and their potential to become chimeric antigen receptor (CAR) T cells, according to data presented during a media preview for the...

gynecologic cancers

AACR 2018: Chlamydia Infection May Be Associated With Increased Risk of Ovarian Cancer

An antibody that is present in the blood of women previously infected with the sexually transmitted infection chlamydia is associated with a doubling in ovarian cancer risk, according to data presented during a media preview for the 2018 American Association for Cancer Research (AACR) Annual...

issues in oncology

AACR 2018: Underserved Populations Lack Information About Clinical Trials, Biobanking

People in Louisiana communities with cancer health disparities would be interested in participating in clinical trials or submitting samples to biobanks if provided information about these opportunities by a trusted physician—but physicians reported lacking appropriate information to give to...

survivorship

Many AYA Cancer Survivors Have More Social Connections Than Peers With No History of Cancer

Survivors of adolescent and young adult (AYA) cancer often have stronger social networks than their peers with no cancer history, according to St. Jude Children’s Research Hospital researchers, who hope to translate that support into better health outcomes for the nation’s...

gynecologic cancers
immunotherapy

FDA Accepts Pembrolizumab sBLA for Treatment of Advanced Cervical Cancer

On March 13, Merck announced that the U.S. Food and Drug Administration (FDA) has accepted a new supplemental biologics license application (sBLA) and granted Priority Review for pembrolizumab (Keytruda), the company’s anti–programmed cell death protein 1 (PD-1) therapy. The application ...

leukemia

Patients With AML Have Reduced Risk of Early Mortality at NCI-Designated Cancer Centers

Researchers at the University of California (UC), Davis, have shown that patients with acute myeloid leukemia (AML) who received their care at a National Cancer Institute (NCI) cancer center in California had a dramatically reduced risk of early mortality. Using data from the California Cancer...

The Anesthesia Era: 1845–1875

  The text and photograph on this page are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photo below is from the volume titled “The Anesthesia Era: 1845–1875.” The photograph...

hematologic malignancies
leukemia

FDA Accepts NDA, Grants Priority Review for Ivosidenib in Relapsed or Refractory IDH1-Mutated AML

On February 15, the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for ivosidenib (AG-120) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation. The NDA was granted Priority Review...

solid tumors
pancreatic cancer

FDA Grants Orphan Drug Designation to YS-ON-001 for the Treatment of Pancreatic Cancer

On February 26, Yisheng Biopharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to its lead immuno-oncology candidate, YS-ON-001, for the treatment of pancreatic cancer.  YS-ON-001 is a clinical-stage immuno-oncology biologic product with...

solid tumors
breast cancer

FDA Approves Abemaciclib as Initial Therapy for Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

On February 26, the U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer. MONARCH 3 Approval...

issues in oncology
survivorship

Seeking Beauty From the Inside Out After Cancer Treatment

  BOOKMARK Title: Autobiography of a FaceAuthor: Lucy GrealyPublisher: Houghton Mifflin HarcourtOriginal Publication Date: June 1994Price: $14.95, paperback; 256 pages We live in a celebrity-obsessed society that is consumed by images of what we perceive as ideal beauty. Numerous studies show that ...

issues in oncology

Fast Food Nation and America’s Sick Diet

BOOKMARK Title: Fast Food Nation: The Dark Side of the All-American MealAuthor: Eric SchlosserOriginal Publisher: Houghton MifflinOriginal Publication Date: January 2001Price: $23.95, paperback, 288 pages     The Centers for Disease Control and Prevention (CDC) estimates that about two-thirds of...

supportive care
palliative care
immunotherapy

The Challenge of Prognostication in the Era of Immunotherapy

  GUEST EDITOR Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD. Dr. Von Roenn is ASCO’s Vice President of Education, Science, and Professional Development. Although advances in such ...

breast cancer
issues in oncology

Breast Cancer Screening Guidelines May Lead to Delayed Diagnosis in Nonwhite Women

The current guidelines for mammographic breast cancer screening, which are based on data from primarily white populations, may lead to delayed diagnosis in nonwhite women, according to a report published by Stapleton et al in JAMA Surgery. A team of Massachusetts General Hospital (MGH)...

prostate cancer

Novel PET Imaging Agent Targets Copper in Tumors, Allowing Early Detection of Prostate Cancer Recurrence

An Italian study featured in The Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse (ie, rising prostate-specific antigen [PSA] level). Copper...

hematologic malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...

issues in oncology

Legal Duties of Clinicians When Terminally Ill Patients With Cancer or Their Surrogates Insist on ‘Futile’ Treatment

Law and Ethics in Oncology explores the legal and ethical issues oncologists must be aware of in this era of precision medicine and changing health-care policy, both to protect patients’ rights and to safeguard against potential legal jeopardy. For years, ASCO and other medical societies have...

National Comprehensive Cancer Network Reports New Milestones, Fosters Novel Collaborations

MORE THAN 8 million copies of the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®) were downloaded in 2017, marking a 16% increase since 2016 and setting a new personal record for the NCCN. Over the past 2 years, free downloads from NCCN.org and the ...

issues in oncology
survivorship

It Starts With a Discussion: ASCO Guideline on Interventions to Address Sexual Problems in People With Cancer

Dr. Katz is a certified sexuality counselor at CancerCare Manitoba, Canada. SEXUALITY AND SEXUAL functioning are important to cancer survivors, and considering the significant number of survivors, this is an issue that should not be ignored. In a survey of cancer survivors who had completed...

University of Pittsburgh Plans to Create New Immunotherapy Facility

THE UNIVERSITY OF PITTSBURGH and its corresponding medical center (UPMC) are once again partnering to advance the pace of life-changing innovation in the region and beyond. The University of Pittsburgh and UPMC leaders announced plans to establish the new UPMC Immune Transplant and Therapy Center...

lung cancer

Osimertinib: A New Standard of Care in Initial Treatment of EGFR-Mutant NSCLC

Dr. Ramalingam is Professor of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta. MUTATIONS IN the epidermal growth factor receptor (EGFR) gene were discovered in 2004. These mutations, localized most commonly to exon 19 or 21, vary in...

breast cancer

Selected Abstracts From the San Antonio Breast Cancer Symposium

EACH YEAR, The ASCO Post asks Jame Abraham, MD, FACP, Director of the Breast Oncology Program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program, to give his picks for the most important research presented at the San Antonio Breast Cancer...

multiple myeloma

EXPERT POINT OF VIEW: Andrzej Jakubowiak, MD, PhD

INTERVIEWED BY The ASCO Post, Andrzej Jakubowiak, MD, PhD, Director of the Multiple Myeloma Program at the University of Chicago Medical Center, commented on the “controversial findings” of EMN02/HO95. “This European study has opened the gate toward showing the benefit of a second transplant,...

hematologic malignancies
lymphoma

Proud to Be a Pioneer in CAR T-Cell Therapy

  Six years ago, I was 38 years old and, like many young people, took life for granted. I had two young daughters, ages 7 years and 4 months, and a wife I adored. And, except for a nagging pain on the left side of my abdomen, I was blessed with good health. Then, suddenly, the pain became so...

Study Uses Music Medicine to Reduce Stress in Pediatric Patients

In a first-of-its-kind collaboration, the Children’s Cancer Association, Randall Children’s Hospital at Legacy Emanuel, and Legacy Research Institute, of Portland, Oregon, co-led a study to assess the impact of using live music as medicine on postoperative pediatric patients to reduce pain and...

Advertisement

Advertisement




Advertisement